ANN ARBOR, Mich., May 17, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded multi-cellular therapies for the treatment of severe, chronic cardiovascular diseases, will present results from two studies of the company’s bone marrow-derived cell therapy product, ixmyelocel-T, in poster presentations on May 19 and 21 at the 17th Annual International Society for Cellular Therapy Meeting in Rotterdam, The Netherlands. The studies provide new insights about the role of mesenchymal stem cells (MSCs) and the function of MAC-1 integrin in the expansion of hematopoietic cells and mesenchymal stem cells.
